Document is current
Any future updates will be listed below
-
Authors
Debily, Marie-Anne https://orcid.org/0000-0002-8509-6165
Le Teuff, Gwenael https://orcid.org/0000-0003-3292-0939
Kergrohen, Thomas
Varlet, Pascale
Castel, David https://orcid.org/0000-0003-0247-080X
Leblond, Pierre https://orcid.org/0000-0002-7088-2614
Hargrave, Darren https://orcid.org/0000-0001-8219-9807
Nysom, Karsten https://orcid.org/0000-0003-2935-0058
Blomgren, Klas https://orcid.org/0000-0002-0476-7271
McCowage, Geoffrey Brian
Bautista, Francisco https://orcid.org/0000-0002-0421-8862
van Vuurden, Dannis
Jones, Chris
Mackay, Alan
Izquierdo, Elisa https://orcid.org/0000-0002-3054-5832
Ziegler, David S. https://orcid.org/0000-0001-7451-7916
Moussa, Angokai
Barret, Emilie
Puget, Stephanie
Beccaria, Kevin
Aquilina, Kristian
Riffaud, Laurent
Bolle, Stephanie https://orcid.org/0000-0003-1311-9214
Abbou, Samuel
Bertozzi, Anne-Isabelle
De Carli, Emilie
Boddaert, Nathalie https://orcid.org/0000-0003-0991-7774
Dangouloff-Ros, Volodia
Calmon, Raphael
Blanc, Patricia
Vassal, Gilles
Le Deley, Marie-Cécile
Grill, Jacques https://orcid.org/0000-0003-4773-3001
- License Information
-
More Information
Article History
Received: 2 October 2025
Accepted: 18 March 2026
First Online: 24 April 2026
Competing interests
: The authors declare that three drugs (everolimus, erlotinib and dasatinib) were supplied free of charge by the pharmaceutical companies (Novartis, F. Hoffman-La Roche and Bristol Myers Squibb, respectively). Novartis also provided a grant to support the conduct of the study. None of these companies had any influence on the authors’ judgments or actions with regard to the objective presentation, analysis and interpretation of the data. The authors declare no other competing interests related to this study.
